Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer

Tetsuo Tani; Ichiro Nakachi; Shinnosuke Ikemura; Shigenari Nukaga; Keiko Ohgino; Aoi Kuroda; Hideki Terai; Keita Masuzawa; Taro Shinozaki; Kota Ishioka; Yohei Funatsu; Hidefumi Koh; Koichi Fukunaga; Kenzo Soejima; Keio Lung Oncology Group (KLOG)

doi:10.2147/CMAR.S330103

Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer

Cancer Manag Res. 2021 Sep 29:13:7497-7503. doi: 10.2147/CMAR.S330103. eCollection 2021.

Authors

Tetsuo Tani^{1

2

3}, Ichiro Nakachi^{1

4}, Shinnosuke Ikemura¹, Shigenari Nukaga^{1

5}, Keiko Ohgino^{1

6}, Aoi Kuroda^{1

7}, Hideki Terai^{1

8}, Keita Masuzawa^{1

8}, Taro Shinozaki¹, Kota Ishioka^{1

9}, Yohei Funatsu^{1

2}, Hidefumi Koh^{1

2}, Koichi Fukunaga¹, Kenzo Soejima^{1

10}; Keio Lung Oncology Group (KLOG)

Affiliations

¹ Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
² Department of Internal Medicine, Tachikawa Hospital, Tokyo, Japan.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Utsunomiya, Tochigi, Japan.
⁵ Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
⁶ Department of Pulmonary Medicine, Kawasaki Municipal Hospital, Kawasaki, Kanagawa, Japan.
⁷ Department of Respiratory Medicine, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan.
⁸ Department of Pulmonary Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
⁹ Department of Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
¹⁰ Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.

Abstract

Background: Metastatic peritoneal carcinomatosis (MPC) is not common in patients with non-small cell lung cancer (NSCLC), and the clinical characteristics and treatment outcomes are still unclear.

Patients and methods: We recruited 46 NSCLC patients with MPC at Keio University and affiliated hospitals (Keio Lung Oncology Group) between January 2011 and December 2017, then retrospectively investigated their clinical characteristics and the impact of treatment interventions on their survival.

Results: The profile of histological subtype was predominantly adenocarcinoma and 15 patients harbored driver oncogenes. Univariate and multivariate analysis demonstrated that performance status and the presence of a driver oncogene were significantly associated with the prolonged overall survival (OS). Regarding treatment, the median OS in the treatment group (9.3 months) was significantly longer than in the best supportive care group (1.3 months) (P < 0.0001).

Conclusion: The prognosis of MPC in NSCLC patients who receive only the best supportive care is poor, but therapeutic intervention may improve prognosis.

Keywords: EGFR; NSCLC; intraperitoneal dissemination; malignant ascites; metastatic peritoneal carcinomatosis; peritoneal nodule.